{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:43:16Z","timestamp":1789062196723,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T00:00:00Z","timestamp":1441324800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s12020-015-0727-2","type":"journal-article","created":{"date-parts":[[2015,9,3]],"date-time":"2015-09-03T06:04:54Z","timestamp":1441260294000},"page":"205-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Treating prolactinomas with dopamine agonists: always worth the gamble?"],"prefix":"10.1007","volume":"51","author":[{"given":"Sean","family":"Noronha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,4]]},"reference":[{"key":"727_CR1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ando.2012.03.024","volume":"73","author":"D Maiter","year":"2012","unstructured":"D. Maiter, V. Primeau, 2012 update in the treatment of prolactinomas. Ann. Endocrinol. 73, 90\u201398 (2012)","journal-title":"Ann. Endocrinol."},{"key":"727_CR2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265\u2013273 (2006)","journal-title":"Clin. Endocrinol."},{"key":"727_CR3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485\u2013534 (2006)","journal-title":"Endocr. Rev."},{"key":"727_CR4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, Endocrine Society, Diagnosis and treatment of hyperprolactinaemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273\u2013288 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"727_CR5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/cen.12242","volume":"79","author":"AB Moraes","year":"2013","unstructured":"A.B. Moraes, C.M. Silva, L. Vieira Neto, M.R. Gadelha, Giant prolactinomas: the therapeutic approach. Clin. Endocrinol. 79, 447\u2013456 (2013)","journal-title":"Clin. Endocrinol."},{"key":"727_CR6","first-page":"2338","volume":"81","author":"BM Biller","year":"1996","unstructured":"B.M. Biller, M.E. Molitch, M.L. Vance, K.B. Cannistraro, K.R. Davis, J.A. Simons, J.R. Schoenfelder, A. Klibanski, Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 81, 2338\u20132343 (1996)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"727_CR7","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"J. Verhelst, R. Abs, D. Maiter, A. van den Bruel, M. Vandeweghe, B. Velkeniers, J. Mockel, G. Lamberigts, P. Petrossians, P. Coremans, C. Mahler, A. Stevenaert, J. Verlooy, C. Raftopoulos, A. Beckers, Cabergoline in the treatment of hyperprolactinaemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518\u20132522 (1999)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"727_CR8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12020-014-0281-3","volume":"47","author":"R Salvatori","year":"2014","unstructured":"R. Salvatori, Surgical treatment of microprolactinomas: pros. Endocrine 47, 725\u2013729 (2014)","journal-title":"Endocrine"},{"key":"727_CR9","unstructured":"Position statement on the use of dopamine agonists in endocrine disorders; Society for Endocrinology, Feb 2009 reviewed Nov 2011"},{"key":"727_CR10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2265.2008.03458.x","volume":"70","author":"N Herring","year":"2009","unstructured":"N. Herring, C. Szmigielski, H. Becher, N. Karavitaki, J.A. Wass, Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin. Endocrinol. 70, 104\u2013108 (2009)","journal-title":"Clin. Endocrinol."},{"key":"727_CR11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-12-0121","volume":"167","author":"A Elenkova","year":"2012","unstructured":"A. Elenkova, R. Shabani, K. Kalinov, S. Zacharieva, Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur. J. Endocrinol. 167, 17\u201325 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"727_CR12","first-page":"99","volume":"77","author":"V Delgado","year":"2012","unstructured":"V. Delgado, N.R. Biermasz, S.W. van Thiel, S.H. Ewe, N.A. Marsan, E.R. Holman, R.A. Feelders, J.W. Smit, J.J. Bax, A.M. Pereira, Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2\u00a0year follow-up study. Eur. J. Endocrinol. 77, 99\u2013105 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"727_CR13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1530\/EJE-13-0231","volume":"169","author":"RS Auriemma","year":"2013","unstructured":"R.S. Auriemma, R. Pivonello, Y. Perone, L.F. Grasso, L. Ferreri, C. Simeoli, D. Iacuaniello, M. Gasperi, A. Colao, Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur. J. Endocrinol. 169, 359\u2013366 (2013)","journal-title":"Eur. J. Endocrinol."},{"key":"727_CR14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ecl.2014.10.007","volume":"44","author":"RS Auriemma","year":"2015","unstructured":"R.S. Auriemma, R. Pivonello, L. Ferreri, P. Priscitelli, A. Colao, Cabergoline use for pituitary tumors and valvular disorders. Endocrinol. Metab. Clin. North Am. 44, 89\u201397 (2015)","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"727_CR15","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1365-2265.2010.03973.x","volume":"74","author":"H Gu","year":"2011","unstructured":"H. Gu, S. Luck, P.V. Carroll, J. Powrie, J. Chambers, Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clin. Endocrinol. 74, 608\u2013610 (2011)","journal-title":"Clin. Endocrinol."},{"key":"727_CR16","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890423349","volume-title":"Diagnostic and Statistical Manual of Mental Disorders\u2014Text Revision (DSM-IV-TR)","author":"American Psychiatric Association (APA)","year":"2000","unstructured":"American Psychiatric Association (APA), Diagnostic and Statistical Manual of Mental Disorders\u2014Text Revision (DSM-IV-TR) (APA, Washington, DC, 2000)"},{"key":"727_CR17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","volume":"104","author":"J Ahlskog","year":"2011","unstructured":"J. Ahlskog, Pathological behaviours provoked dopamine agonist therapy of Parkinson\u2019s disease. Physiol. Behav. 104, 168\u2013172 (2011)","journal-title":"Physiol. Behav."},{"key":"727_CR18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","volume":"69","author":"P Seeman","year":"2015","unstructured":"P. Seeman, Parkinson\u2019s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69, 183\u2013189 (2015)","journal-title":"Synapse"},{"key":"727_CR19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7861\/clinmedicine.14-2-205","volume":"14","author":"VS Premaratne","year":"2014","unstructured":"V.S. Premaratne, I. Saeger, B.K. Macdonald, Lesson of the month (1): cabergoline - \u2018I eat funny on that\u2019. Clin. Med. 14, 205\u2013507 (2014)","journal-title":"Clin. Med."},{"key":"727_CR20","first-page":"81","volume":"33","author":"JR Cornelius","year":"2010","unstructured":"J.R. Cornelius, M. Tippmann-Peikert, N.L. Slocumb, C.F. Frerichs, M.H. Silber, Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 33, 81\u201387 (2010)","journal-title":"Sleep"},{"key":"727_CR21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/CPJ.0b013e318278be9b","volume":"2","author":"HD Weiss","year":"2012","unstructured":"H.D. Weiss, L. Marsh, Impulse control disorders and compulsive behaviours associated with dopaminergic therapies in Parkinson\u2019s disease. Neurol. Clin. Pract. 2, 267\u2013274 (2012)","journal-title":"Neurol. Clin. Pract."},{"key":"727_CR22","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0924-9338(10)70672-6","volume":"25","author":"A Nevely","year":"2010","unstructured":"A. Nevely, A. Frei, M. Graf, PO2-58: sexual misconduct induced by iatrogenic hyperprolactinaemia. Eur. Psychiatry 25, 678 (2010)","journal-title":"Eur. Psychiatry"},{"key":"727_CR23","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"T.J. Moore, J. Glenmullen, D.R. Mattison, Reports of pathological gambling, hypersexuality and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern. Med. 174, 1930\u20131933 (2014)","journal-title":"JAMA Intern. Med."},{"key":"727_CR24","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2015","unstructured":"Joint Formulary Committee, British National Formulary, 68th edn. (BMJ Group and Pharmaceutical Press, London, 2015)","edition":"68"},{"key":"727_CR25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","volume":"19","author":"M Davie","year":"2007","unstructured":"M. Davie, Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J. Neuropsychiatry Clin. Neurosci. 19, 473\u2013474 (2007)","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"727_CR26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5694\/j.1326-5377.2009.tb02289.x","volume":"190","author":"H Falhammar","year":"2009","unstructured":"H. Falhammar, J.Y. Yarker, Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med. J. Aust. 190, 97 (2009)","journal-title":"Med. J. Aust."},{"key":"727_CR27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0031-1281580","volume":"79","author":"M Gahr","year":"2011","unstructured":"M. Gahr, B.J. Connemann, C.J. Sch\u00f6nfeldt-Lecuona, Pathological gambling induced by dopamine agonists. Fortschr. Neurol. Psychiatr. 79, 470\u2013474 (2011)","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"727_CR28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/WNF.0b013e31829fc165","volume":"36","author":"SK Thondam","year":"2013","unstructured":"S.K. Thondam, S. Alusi, K. O\u2019Driscoll, C.E. Gilkes, D.J. Cuthbertson, C. Daousi, Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clin. Neuropharmacol. 36, 170\u2013172 (2013)","journal-title":"Clin. Neuropharmacol."},{"key":"727_CR29","unstructured":"A. Gupta, R.S. Zimmerman, Hypersexuality in cabergoline-treated prolactinoma, 93rd Annual Meeting of the Endocrine Society: abstr. P3-312, 2011"},{"key":"727_CR30","unstructured":"M.R. Nannenga, P.J. Tebben, T.B. Nippoldt, Development of impulse control disorders in patients with dopamine agonist-treated prolactinomas: a case series. 93rd Annual Meeting of the Endocrine Society: abstr. P3-311, 2011"},{"key":"727_CR31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","volume":"34","author":"J Martinkova","year":"2011","unstructured":"J. Martinkova, L. Trejbalova, M. Sasikova, J. Benetin, P. Valkovic, Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin. Neuropharmacol. 34, 179\u2013181 (2011)","journal-title":"Clin. Neuropharmacol."},{"key":"727_CR32","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.rbp.2012.03.001","volume":"34","author":"MC Viana","year":"2012","unstructured":"M.C. Viana, L.H. Andrade, Lifetime prevalence, age and gender distribution and age-of-onset of psychiatric disorders in the Sao Paolo metropolitan area, Brazil: results from Sao Paolo Megacity Mental Health Survey. Rev. Bras. Psiquiatr. 34, 249\u2013260 (2012)","journal-title":"Rev. Bras. Psiquiatr."},{"key":"727_CR33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","volume":"17","author":"M Barake","year":"2014","unstructured":"M. Barake, A.E. Evins, L. Stoeckel, G.N. Pachas, L.B. Nachtigall, K.K. Miller, B.M. Biller, N.A. Tritos, A. Klibanski, Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary 17, 150\u2013156 (2014)","journal-title":"Pituitary"},{"key":"727_CR34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"I. Bancos, M.R. Nannenga, J.M. Bostwick, M.H. Silber, D. Erickson, T.B. Nippoldt, Impulse control disorders in patients with dopamine agonist-treated prolactinomas and non-functioning pituitary adenomas: a case\u2013control study. Clin. Endocrinol. 80, 863\u2013868 (2014)","journal-title":"Clin. Endocrinol."},{"key":"727_CR35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000335996","volume":"96","author":"AP Athanasoulia","year":"2012","unstructured":"A.P. Athanasoulia, M. Ising, H. Pfister, C.S. Mantzoros, G.K. Stalla, C. Sievers, Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinology 96, 204\u2013211 (2012)","journal-title":"Neuroendocrinology"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0727-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-015-0727-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-015-0727-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T23:03:44Z","timestamp":1599519824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-015-0727-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1007\/s12020-015-0727-2","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,4]]}}}